MW: 375.41. Purity ≥99%. Background: ABT-869 is multi-targeted inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR, IC?? value of 4 nM), but has much less activity (IC?? values >1 uM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases. The kinase inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC?? values of 2, 4 and 7 nM for PDGFRbeta, KDR and CSF-1R, respectively) and VEGF-stimulated pr